for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Athenex Inc

ATNX.OQ

Latest Trade

13.00USD

Change

0.29(+2.28%)

Volume

194,708

Today's Range

12.76

 - 

13.07

52 Week Range

5.63

 - 

18.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.71
Open
12.78
Volume
194,708
3M AVG Volume
16.90
Today's High
13.07
Today's Low
12.76
52 Week High
18.33
52 Week Low
5.63
Shares Out (MIL)
93.34
Market Cap (MIL)
1,263.81
Forward P/E
-8.58
Dividend (Yield %)
--

Next Event

Athenex Inc Annual Shareholders Meeting

Latest Developments

More

Athenex Posts Q3 Loss Per Share Of $0.44

Axis Therapeutics Announces Research Collaboration With Pharmaessentia For Development Of Tcr-T Cell Therapy In Taiwan

Athenex Announces Pricing Of $110 Million Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Athenex Inc

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Industry

Biotechnology & Drugs

Contact Info

1001 Main St Ste 600

BUFFALO, NY

14203-1009

United States

+1.716.8988625

https://www.athenex.com/

Executive Leadership

Johnson Y.N. Lau

Chief Executive Officer and Chairman of the Board

Randoll Sze

Chief Financial Officer

William W. Zuo

President, China Division

Jeffrey M. Yordon

Chief Operating Officer and President, Athenex Pharmaceutical Division

Daniel Lang

Senior Director - Corporate Development, President - Axis Therapeutics Limited

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-2.630

2018

-1.820

2019

-1.670

2020(E)

-1.579
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.05
Price To Book (MRQ)
5.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
54.76
LT Debt To Equity (MRQ)
53.93
Return on Investment (TTM)
-42.57
Return on Equity (TTM)
-34.55

Latest News

Latest News

BRIEF-Athenex Announces $225 Million Loan Agreement With Oaktree

* ATHENEX INC - PORTION OF UPFRONT LOAN PROCEEDS BEING USED TO REPAY IN FULL EXISTING DEBT FACILITY

BRIEF-Athenex Says Entered Into $225 Million Senior Secured Loan Agreement

* ATHENEX INC - ON JUNE 19, ENTERED INTO $225 MILLION SENIOR SECURED LOAN AGREEMENT

BRIEF-Athenex Presents Interim Data From Oral Paclitaxel Phase Ii Study In Cutaneous Angiosarcoma At Asco20 Virtual Scientific Program

* ATHENEX PRESENTS INTERIM DATA FROM ORAL PACLITAXEL PHASE II STUDY IN CUTANEOUS ANGIOSARCOMA AT ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Athenex Q1 Loss Per Share $0.24

* ATHENEX, INC. REPORTS FIRST QUARTER ENDED MARCH 31, 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Athenex On Track To Submit NDA For Oral Paclitaxel And Encequidar

* ATHENEX INC - ON TRACK TO SUBMIT NDA FOR ORAL PACLITAXEL AND ENCEQUIDAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Athenex Says Arrangement With CEO Johnson Lau, Whereby Lau To Receive Options To Buy Co's Shares In Lieu Of Portion Of Remaining Base Salary For 2020

* ATHENEX - ARRANGEMENT WITH CEO JOHNSON LAU, WHEREBY LAU TO RECEIVE OPTIONS TO BUY CO'S SHARES IN LIEU OF PORTION OF REMAINING BASE SALARY FOR 2020

BRIEF-Athenex Inc's Operational Plans Continue To Remain On Track

* ATHENEX INC - OPERATIONAL PLANS CONTINUE TO REMAIN ON TRACK

BRIEF-Athenex Announces FDA Acceptance For Filing Of U.S. NDA For Tirbanibulin Ointment In Actinic Keratosis

* ATHENEX ANNOUNCES FDA ACCEPTANCE FOR FILING OF U.S. NDA FOR TIRBANIBULIN OINTMENT IN ACTINIC KERATOSIS

BRIEF-Athenex, Inc. Reports Q4 Loss Per Share $0.28

* ATHENEX, INC. REPORTS FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Pricing Of Offering Of Common Stock

* ATHENEX, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

BRIEF-Athenex Announces Proposed Offering Of Common Stock

* SAYS OFFERING 4.30 MILLION COMMON SHARES Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol

* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER

BRIEF-Athenex Files For Offering Of Up To 4.3 Million Shares

* ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING Source text : (http://bit.ly/2Dr3FzB) Further company coverage:

BRIEF-Athenex Announces`Results Of First Cohort Of Phase I Clinical Trial Of Gastric Cancer Treatment

* ATHENEX ANNOUNCES ENCOURAGING RESULTS OF THE FIRST COHORT OF PHASE I CLINICAL TRIAL OF ORAXOL AND CYRAMZA® (RAMUCIRUMAB) COMBINATION TREATMENT IN GASTRIC CANCER Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up